Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Peptides for use in the treatment of viral infections

一种病毒感染、病原体感染的技术，应用在用于治疗病毒感染的肽领域，能够解决不能解决致死性细胞因子风暴等问题

Pending Publication Date: 2020-05-15
YISSUM RES DEV CO OF THE HEBREW UNIV OF JERUSALEM LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

These antiviral drugs do not address the lethal cytokine storm associated with infection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Peptides for use in the treatment of viral infections
  • Peptides for use in the treatment of viral infections
  • Peptides for use in the treatment of viral infections

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0229] The peptides defined herein can be synthesized using standard methods known in the art. Direct synthesis of the peptides of the invention can be accomplished using solid phase peptide synthesis, solution phase synthesis, or other conventional means. For example, in solid-phase synthesis, appropriately protected amino acid residues are linked via their carboxyl groups to an insoluble polymeric support, such as cross-linked polystyrene or polyamide resins. In this context, a protected amino acid means that protecting groups are present on the amino group of the amino acid as well as on any side chain functional groups. The advantage of side chain protecting groups is that they are generally stable to the solvents, reagents and reaction conditions used throughout the synthesis and are removable without affecting the final peptide product. Typically, stepwise synthesis of polypeptides is carried out by removing the N-protecting group from the starting carboxy-terminus and ...

example 1

[0264] Protective effect of CD28 dimer interface peptide against lethal H5N1 avian influenza infection

[0265] As mentioned above, current treatment strategies for H5N1 infection mainly focus on neuraminidase inhibitors (eg, the FDA-approved antiviral drug oseltamivir), but the virus rapidly mutates to become resistant. A variety of treatments aim to manipulate the host immune system to interfere with and prevent the cytokine storm caused by the activation of pro-inflammatory Th1 cells derived from viral pathogens (eg: H5N1) antigens, as well as combined therapies targeting both the virus and the host, the Combination therapy may have greater potential in controlling and preventing cytokine storm-related diseases.

[0266] Therefore, the inventors investigated whether the inhibition of superantigen-induced Th1 cell activation by short peptides derived from the dimer interface of human CD28 could reduce or prevent the cytokine storm caused by Th1 cytokines, and thus could be u...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed are peptides, compositions, combinations, kits and methods for the treatment of viral pathogen infection. Combinations and kits comprise the disclosed peptides together with an additional antiviral therapeutic agent.

Description

technical field [0001] The invention discloses methods, compounds, combinations and uses thereof for treating infections caused by viral pathogens, including Orthomyxoviridae viruses, particularly influenza A and B, filoviruses Viruses of the family Flaviviridae or Flaviviridae. The presently disclosed methods, compounds, combinations and uses specifically employ various short peptides that specifically bind CD28, and synergistic combinations of said short peptides with antiviral agents. Background technique [0002] References believed to be relevant to the presently disclosed subject matter are listed below: [0003] [1] Osterholm, M.T. (2005) N.Engl.J.Med.352, 1839-1842 [0004] [2] Kobasa, D. et al. (2004) Nature 431, 703-707 [0005] [3] Oxford, J.S., Rev. Med. Virol.10, 119-133 (2000) [0006] [4] Cheung, C.Y. et al. (2002) Lancet 360, 1831-1837 [0007] [5] Peiris, J.S. et al. (2004) Lancet 363, 617-619 [0008] [6] WO 2004 / 087196 [0009] [7]US2017 / 0189529 ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/04C07K7/06A61P31/16A61P31/12
CPCC07K7/06A61P31/16A61P31/12A61K38/1774A61K31/215A61K31/7012A61K2300/00A61K31/351A61K38/08A61K45/06
Inventor 雷蒙德·凯伯弗吉拉·阿拉德
Owner YISSUM RES DEV CO OF THE HEBREW UNIV OF JERUSALEM LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com